secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-093961
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports Q4 net loss $44.9M, cash $301.8M; HCV Phase 3 topline mid-2026; HEV program mid-2026
--------------------------------------------------------------------------------

- Net loss $44.9M in Q4 2025 (EPS -$0.57) vs $33.5M loss in Q4 2024; full-year net loss $158.3M.
- Cash and investments $301.8M at Dec 31, 2025, down from $454.7M a year ago.
- R&D expense $47.8M in Q4, up from $25.7M YoY, driven by HCV Phase 3 spend including milestone to Merck.
- Global Phase 3 HCV program: C-BEYOND (enrolled >880) topline mid-2026; C-FORWARD enrollment complete mid-2026, topline year-end 2026.
- Expanded antiviral pipeline: HEV program with AT-587 expected to enter clinic mid-2026; presented in vitro data at CROI 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312526093961/0001193125-26-093961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312526093961/d118938d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-093961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer